- November 13, 2017 Spero Therapeutics Announces Underwriters’ Option Exercise
- November 06, 2017 Spero Therapeutics Announces Closing of Initial Public Offering
- November 01, 2017 Spero Therapeutics Announces Pricing of Initial Public Offering
- October 23, 2017 Spero Therapeutics Launches Initial Public Offering
- October 20, 2017 Spero Therapeutics Initiates Clinical Program For Oral Carbapenem SPR994
- October 10, 2017 Spero Therapeutics Licenses Exclusive Rights to SPR994, a Novel Oral Carbapenem Being Studied for Use in Adults
- October 06, 2017 Spero Therapeutics Files Registration Statement for Proposed Initial Public Offering
- October 03, 2017 Spero Therapeutics Announces Positive Phase 1 Clinical Data From Potentiator Platform
- September 06, 2017 Spero Announces Appointment of Frank Thomas to its Board of Directors and Promotions within Leadership Team
- July 11, 2017 Spero Therapeutics to Participate in Anti-Infectives Panel Discussions at the 2017 Infectious Disease Summit
Displaying 31 - 40 of 72 results